

Alessandra Mangia, MD

List of publications

1. Mangia A. Biomarkers use and development in Hepatology: insights on the latest applications. Cells 2023 doi: [10.3390/cells12010104](https://doi.org/10.3390/cells12010104)
2. Fagioli S, Toniutto P, Coppola N et al Italian Real world analysis of the impact of polypharmacy and aging on the risk of multiple drug to drug interactions (DDI) in HCV patients treated with pangenotypic direct acting antivirals. Therapeutics and clinical risk management 2023. doi: [10.2147/tcrm.s394467](https://doi.org/10.2147/tcrm.s394467)
3. Mangia A, Piazzolla AV, Squillante MM, et al Nonalcoholic steatohepatitis: a 9-year follow-up cohort study. Journal of Clinical Medicine 2022; doi: 10.339/jcm11195969
4. Giambra V, Piazzolla AV, Cocomazzi G, MM Squillante et al Effectiveness of booster dose of antiSARS-CoV-2-BNT162b2 in cirrhosis: longitudinal evaluation of humoral and cellular response. Vaccines 2022; doi: 10.3390/vaccines10081281
5. Rosati S, Wong A, Di Marco V et al Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings Future Virology 2022;17:7
6. Mangia A, Serra N, Cocomazzi G, Giambra V et al Cellular and humoral Immune responses and breakthrough infections after two doses of BNT162b vaccine in healthcare workers (HW) 180 days after the second vaccine dose. Frontiers Public Health 2022; 10 doi: 10.3389/fpubh.2022.847384
7. Mendez-Sanchez N, Bugianesi E, Gish RG, Lammert F, et al Global multistakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 2022; 7: P388-390
8. Indolfi G, Kelly D, Nebbia G, Iorio R et al Sofosbuvir-Velpatasvir-voxilaprevir in adolescent 12 to 17 years old with hepatitis C virus infection Hepatology 2022;
9. Barret L, Rosati S, Garcia-Retortillo M, Wedemeyer H et al Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved populations because of mental health disorders, incarceration or homelessness. Ann Hepatol 2022; 27: 100647
10. Andreoni M, Coppola N, Craxì A, Fagioli S et al Meet-test-treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy. BMC Infect Dis 2022; 22: 3
11. Valencia A, Vergara C, Thio C, Vince N et al Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQB1. Am J Hum Genet 2022; 109: 299-310

12. Mangia A, Rina MF, Canosa A, Piazzolla V, Suillante MM et al Increased hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy. *UEG Journal* 2021; 9:1109-1118
13. Ferrari D, Mangia A, Spanò MS, Zaffarano L et al Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign *Clinical Chemistry and Laboratory Medicine* 2021; 59: 2019-2026
14. Francque SM, Bedossa P, Ratziu V, Anstee Q et al A randomized, controlled trial of the Pan PPAR agonist lanifibranor in NASH *NEJM* 2021; 385:1547-1558
15. Colucci M, De Santis E, Totti B, Miroballo M et al Associations between allelic variants of the human IgH 3' regulatory region 1 and the immune response to BNT162b2 mRNA vaccine. *Vaccines* 2021; 9: 1207
16. Ferrari D, Clementi N, Spanò SM, Abitar-Nehme S et al Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects. *Clinica chimica Acta* 2021; 522: 144-151
17. Cocomazzi G, Piazzolla V, Squillante MM, Antinucci S et al Early serological response to BNT162b2 mRNA vaccine in Healthcare workers. *Vaccines* 2021; 9:913
18. Cataldo I, Sarcognato S, Sacchi D, Cacciatore M, et al Pathology of non-alcoholic fatty liver disease. 2021; 113: 194-202
19. Sarcognato S, Sacchi D, Grillo F, Cazzagon N et al Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. *Pathologica* 2021; 113:170-184
20. Mangia A, Scaglione F, Toniutto P, Pirisi M Drug-drug interactions in Italian patients with chronic hepatitis C treated with pangenotypic direct acting agents: insights from a real-world study. *Int J Environ Res and Public Health* 2021; 18: 7144
21. Mangia A, Piazzolla V 2021 Current management of patients with HCV genotype 2 Hepatitis C care and treatment. In: Hatzakis, A. (eds) *Hepatitis C: Care and Treatment*. Springer, Cham
22. Piazzolla V, Paroni G, Bazzocchi F, Cassese M, et al High rates of hidden HCV infections among hospitalized patients aged 55-85. *Pathogens* 2021; 10: 695
23. Mangia A, Cotugno R, Cocomazzi G, Squillante MM et al Hepatitis C microelimination: where do we stand? *World J Gastroenterol* 2021; 27:1728-1737
24. Chuang W-L, Hu T-H, Buggish P, Moreno C, et al Ledipasvir/sofosbuvir for 8, 12 or 24 weeks in hepatitis C patients undergoing dialysis for end stage renal disease *Am J Gastroenterol* 2021; 116: 1924-1928
25. Grandone, E, Tiscia G, Pesavento R, De Lorenzo A et al Use of molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation. *J of Thrombosis and Thrombolysis* 2021; 52:772-778
26. Mangia A, Albanese AP, Bourliere M, Craxi A et al Guidelines have a key role in driving HCV elimination pathways. *Advances in Therapy* 2021; 38: 1397-1403

27. Mangia A, Cenderello G, Verrucchi G, Ciano A et al Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis? *World J of Clinical Cases* 2020; 8:5831-5834
28. Vergara C, Dugal P, Thio CL Multi-ancestry fine mapping of interferon lambda and the the outcome of acute hepatitis C virus infection *Genes and Immunity* <https://doi.org/10.1038/s41435-020-00115-3>
29. Vergara C, Valencia A, Thios C et al A multi-ancestry sex stratified genome-wide association study of spontaneous clearance of hepatitis C virus. *The Journal of Infectious diseases* 2020; doi.org/10.1093/infdis/jiaa677
30. Kuscuoglu D, Bewersdorf L, Wenzel K, Gross A et al Dual proteotoxic stress accelerates liver injury via activation of p62-Nrf2 *J Pathology* 2020 in press
31. Mangia A et al Hepatocellular carcinoma in Adult Thalassemia patients: An expert opinion based on current evidence *BMC gastroenterology* 2020, 20:52
32. Turnes J, Hezode C, Hernandez C, Mangia A. Now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority. *Alimentary Pharmacology and Therapeutics* 2020; 52:1096-1097
33. Mangia A HBV to stop or not to stop *NUCS Liver International* 2019; 12:15
34. Mangia A, Milligan S, Khalili M, Fagioli S et al Global Real-World Evidence of sofosbuvir/velpatasvir as Simple, Effective HCV Treatment: Analysis of 5552 Patients From 12 Cohorts *Liver Int* 2020 May 25. doi: 10.1111/liv.14537. Online ahead of print
35. Piazzolla V, Mangia A. Noninvasive Diagnosis of NAFLD and NASH *Cells* 2020 Apr 17;9 (4):1005. doi: 10.3390/cells9041005
36. Santoro R, Mangia A. Progress in promising anti-fibrotic therapies. *Expert Rev Gastroenterol Hepatol.* 2019 Dec;13 (12):1145-1152.
37. Younossi ZM, Stepanova M, Lawitz EJ, Reddy KR, Wai-Sun Wong V, Mangia A, Muir AJ, Jacobson I, Djedjos CS, Gaggari A, Myers RP, Younossi I, Nader F, Racila A. Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. *Am J Gastroenterol.* 2019 Oct;114(10):1636-1641.
38. Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V, Carraturo I, Potenza D, Napoli N, Lauletta G, Tagarielli V, Santoro R, Piccigallo E, De Gioia S, Chimenti A, Cuccorese G, Metrangola A, Mazzola M, Agostinacchio E, Mennea G, Sabbà C, Cela M, Copetti M, Losappio R. SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. *PLoS One.* 2019 May 15;14(5):e0215783.
39. Peiffer KH, Kuhnhen L, Stelzl E, Dietz J, Susser S, Tal AO, Finkelmeier F, Zuckerman E, Cornberg M, Barak M, Piazzolla V, Mangia A, Zeuzem S, Kessler HH, Vermehren J, Sarrazin C. Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. *J Clin Microbiol.* 2019 Jun 25;57(7).
40. Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciano A SVR12 Higher than 97% in GT3

Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. *Cells*. 2019 Apr 4;8(4).

41. Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. *Gastroenterology*. 2019 Jul;157(1):227-241.e7.
42. Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M, Abate ML, Irving WL, Sheridan D, Dore GJ, Spengler U, Lampertico P, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Santoro R, Gallego-Durán R, Fischer J, Nattermann J, D'Ambrosio R, McLeod D, Powell E, Latchoumanin O, Thabet K, Najim MAM, Douglas MW, Liddle C, Qiao L, George J, Eslam M; A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β 1 dependent mechanisms *Sci Rep*. 2019 Feb 5;9(1):1439.
43. Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuisink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiayaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; GIANT-B Global Consortium Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. *Clin Infect Dis*. 2019 Nov 13;69(11):1969-1979.
44. Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P. Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. *Gastroenterology*. 2019 Apr;156(5):1496-1507.e7.
45. Di Marco V, Alberti A, Angarano G, Colombo M, Di Perri G, Gaeta GB, Ippolito G, Mangia A, Pasqualetti P, Craxì A. Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus. *Eur Rev Med Pharmacol Sci*. 2018 Oct;22(20):7024-7033.
46. Alberti A, Angarano G, Colombo M, Craxì A, Di Marco V, Di Perri G, Gaeta GB, Ippolito G, Mangia A, Pasqualetti P. Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. *Clin Res Hepatol Gastroenterol*. 2019 Apr;43(2):190-200.
47. Mangia A, Losappio R, Cenderello G, Potenza D, Mazzola M, De Stefano G, Terreni N, Copetti M, Minerva N, Piazzola V, Bacca D, Palmieri V, Sogari F, Santoro R. Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced

fibrosis/cirrhosis. PLoS One. 2018 Jul 31;13(7):e0200568. doi: 10.1371/journal.pone.0200568. eCollection 2018.

48. Gaeta GB, Aghemo A, Menzaghi B, D'Offizi G, Giorgini A, Hasson H, Brancaccio G, Palma M, Termini R; STIly Study Group. Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study. *Medicine (Baltimore)*. 2018 Jul;97(27):e11307. doi: 10.1097/MD.00000000000011307.
49. El Sharkawy R, Thabel K, Lampertico P, Petta S, Mangia A et al A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. *Alimentary Pharmacol Ther* 2018; Jul 2: doi:10.1111/apt.14866 I.F. 7.36.
50. Gossens N, DeVito C, Mangia A, Clement S, Cenderello G et al Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: a multicentre study and systematic review. *J Viral Hep* 2018, Mar 13:10:111/jvh.12891 I.F. 4.12.
51. Boni C, Vecchi A, Rossi M, Laccabue D, giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto M, Coco B, Cavallone D, Mangia A et al TLR agonist increases response of hepatitis B virus specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues *Gastroenterology* 2018; 154:1764-77 I.F. 20.77.
52. Huang H, Duggal P, Thio CL, Ladanich R, Goedert J, Mangia A et al. Fine mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. *Sci Rep* 2017; 20:15843 I.F. 5.47.
53. Bhardwaj K, Ragonnet-Cronin M, Murrell B, Chodevarapu K, Martin R, Chang S, Miller MD, Feld J, Sulkowski M, Mangia A et al Inpatients viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. *J Viral Hep* 2018; 25:344-353 I.F. 4.12.
54. John M, Metwally M, Mangia A, Romero-Gomez M, Berg T et al TLL1 rs17047200 increases the risk of fibrosis Progression in Caucasian Patients with chronic hepatitis C. *Gastroenterology* 2017; 153:1448-1449 I.F. 20.77.
55. Mangia A, Piazzolla V Editorial: good news to patients with thalassemia-HCV clearance made easy with direct acting antivirals. Authors' reply. *Aliment Pharmacol Ther* 2017; 46:629-630 I.F. 7.36.
56. Carrai P, Morelli C, Cordone G, Romano A, Tamè M, Lionetti R, Pitrosi G, Lenci I, Piai G, Russo FP, Coppola C, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP et al The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. *Transpl Int* 2017;30: 1253-265 I.F. 3.19.
57. Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Ousinski A, Brainard DM, Subramanian GM, Gane EJ, Feld J, Mangia A Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. *Liver Int* 2018; 38:443-450 I.F. 4.5.
58. Mangia A, Sarli R, Gamberini MR, Piga A, Cenderello G et al Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassemia and HCV genotype 1 or 4 infection. *Aliment Pharmacol Ther* 2017; 46:424-431 I.F. 7.36.

59. Wyles D, Mangia A, Chen W, Sahafran S et al Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor ledipasvir without sofosbuvir. *Antivir Ther* 2017; Jun 26 doi 10.3851 I.F. 2.14.
60. Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzola V, Howe A, et al Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras *J Hepatol* 2017;67:680-686 I.F.14.91.
61. Mangia A, Foster G, Berg T, Curescu M et al Efficacy and safety profile of boceprevir-o telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. *Ann Gastroenterol* 2017; 30:327-343 I.F. 1.25.
62. Slam M, McLeod D, Kelaeng KS, Mangia A et al IFN- λ 3, not IFN- λ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. *Nat Genet.* 2017 May;49(5):795-800. doi: 10.1038/ng.3836. Epub 2017 Apr 10 I.F. 32.1.
63. Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, Antonelli A, Desbois AC, Comarmond C, Gragnani L, Casato M, Lamprecht P, Mangia A et al International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. *Autoimmun Rev* 2017; 16:523-541 I.F. 8.4.
64. Ramos-Casals M, Zignego AL, Ferri C, Brito-Zerón P, Retamozo S, Casato Lamprecht P, Mangia A, Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. *J Hepatol.* 2017 Feb 20. pii: S0168-8278(17)30105-8. doi: 10.1016/j.jhep.2017.02.010. I.F. 11.33
65. Thabet K, Chan HL, Petta S, Mangia A, et al The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. *Hepatology.* 2017 Jan 20. doi: 10.1002/hep.29064. [Epub ahead of print] I.F. 11.19.
66. Zeuzem S, Mizokami M, Pianko S, Mangia A, et al NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. *J Hepatol.* 2017 May;66(5):910-918. doi: 10.1016/j.jhep.2017.01.007. I.F.11.33.
67. Di Maio VC, Cento V, Lenci I, et al HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. *Liver Int.* 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20 I.F.4.47.
68. Mangia A, Susser S, Piazzola V, Agostinacchio E, De Stefano G et al Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. *J Hepatol.* 2017 Apr;66(4):711-717. doi: 10.1016/j.jhep.2016.12.002. I.F.11.33.
69. Mangia A, Ledhingen V, Bailly F, Brahm J et al L28B genotype is associated with cirrhosis or transition to cirrhosis in treatment naive patients with chronic HCV

genotype 1 infection: the international observational Gen-C study Springerplus. 2016 Nov 18;5(1):1990. eCollection 2016.

70. Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, Mangia A et al Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients with HCV Infection, Without or with Compensated or Decompensated Cirrhosis. *Clin Gastroenterol Hepatol.* 2017 Mar;15(3):421-430.e6. doi: 10.1016/j.cgh.2016.10.03. Pub 2016 Nov 12 I.F. 7.6.
71. Ferri C, Ramon-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A et al International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement *Autoimmun Rev* 2016; doi:10.1016/j.autorev.2016.09.006 I.F.10.13.
72. Thabet K, Asimakopoulos A, Shojaei M, Romero Gomez M, Mangia A et al MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. *Nat Commun* 2016 doi:10.1038/ncomms 1275 I.F. 7.39.
73. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, et al Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials *Clin Infect Dis* 2016 Aug 23 I.F.8.80
74. Yonoussi Z, Stephanova M, Sulkowsky M, Foster GR, Reau N, Mangia A et al Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patients reported outcomes in patients with genotype 2 and 3 chronic hepatitis C. Results from Astral-2 and -3 Clinical trials. *Clin Infect Dis* 2016, Oct 15; 63; 1042-8 I.F.8.80
75. Ripoli M, Angelico R, Sacco P, Ceglie A, Mangia A. Phytoliposome-based silibinin delivery system as a promising strategy to prevent hepatitis C virus infection. *J Biomed Nanotechnol* 2016 12; 770-780 I.F.5.33
76. AISF position paper on liver transplantation and pregnancy: Women in Hepatology group, Italian Association for the study of the Liver (AISF) Women in Hepatology Group; Italian Association for the Study of liver (AISF) *Dig Liver Dis* 2016, 48; 860-868 I.F.0.09.
77. Asimakopoulos A, Mangia A, Dore GJ, Lloyd AR, George J, Eslam M. Polymorphisms in STAT4 are associated with treatment response and spontaneous clearance of hepatitis C virus in Europeans *Hepatology* 2016; Apr 17 doi:10.1002/hep.28626 I.F. 11.055.
78. Foster GR, Coppola C, Derbala M, Ferenci P et al Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: results from the GUARD-C Cohort *PlosOne* 2016; doi:10.1371 IF2.80.

79. Foster GR, Mangia A, Sulkowsky M Sofosbuvir and Velpatasvir for patients with HCV infection *N Eng J Med* 2016; 374:1687-8 I.F. 55.87.
80. Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ et al Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes *Hepatology* 2016; Jan 28.doi: 10.1002/hep.28475 I.F. 11.055.
81. Arleo A, Mangia A The current treatment of hepatitis C *Minerva Gastroenterol Dietol.*2016; 62:167-82. IF.0.34.
82. Mangia A, Arleo A, Copetti A, Miscio M et al. The combination of daclatsvir and sofosbuvir for curing genotype2 patients who cannot tolerate ribavirin *Liver Intern* 2016; doi:10.1111/liv.13069. I.F. 4.447.
83. Saab S, Park SH, Mizokami M, Omata M, Mangia A et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. *Hepatology* 2016; 63:1112-9. I.F. 11.055.
84. Di Maio, Cento V, Di Paolo D et al HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV RNA levels *J Antimicrob Chemother* 2016; 71:739-50 I.F. 4.98.
85. Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A et al FibroGENE: a gene-based model for staging liver fibrosis *J Hepatol* 2016; 64:390-398. I.F. 11.33.
86. Foster GR, Afdhal N, Roberts SK, Brau N et al Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection *N Engl J Med* 2015;2608-17 I.F. 59.55.
87. Feld JJ, Jacobson I, Hezode C, Asselah T, et al Sofosbuvir and velpatasvir for HCV genotype 1 2,4, 5 and 6 infection *N Eng J Med* 2015;373: 2599-2607 I.F. 59.55.
88. Lepida A, Colombo M, Fernandez I, Abdurakhmanov D, Abrao Ferreira P, Strasser S, Urbanek P Mangia A et al Final results of the Telaprevir access program FibroScan Values Predict Safety and Efficacy in hepatitis C patients with advanced fibrosis or cirrhosis *Plos One* 2015, 10(9): E0138503 I.F.3.73.
89. Capone F, Guerriero E, Colonna G, Maio P, Mangia A, Marfella R, Paolisso G, Izzo F, Potenza N, Tomeo L, Castello G, Costantini S. The Cytokine Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. *PLoS One*. 2015 Jul 30;10(7): e0134594. doi: 10.1371/journal.pone.0134594. eCollection 2015 IF 3.25.

90. Ascione A, Bruno S, Coppola C, Mangia A, et al Treatment Outcomes and Predictors of Response in Treatment-Naïve HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort. *Hepatogastroenterology*. 2014 Jun;61(132):1094-106 I.F.0.32.
91. Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A et al Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. *Hepatology*. 2015 Jul;62(1):25-30. doi: 10.1002/hep.27890. Epub 2015 Jun 1. I F 11.055.
92. Bertino G, Demma S, Ardiri A, Proiti M, Mangia A et al The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. *Biomed Res Int*. 2014; 2015:731469. doi: 10.1155/2015/731469. Epub 2015 Mar 29. Review IF 1.579.
93. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, et al Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. *Hepatology*. 2015 Jul;62(1):79-86. doi: 10.1002/hep.27826. Epub 2015 May 9 I F 11.055.
94. Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A et al. Interferon- λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. *Nat Commun*. 2015 Mar 5;6:6422. doi: 10.1038/ncomms7422 I F 10.74.
95. De Re V, Caggiari L, De Zorzi M, Repetto O, Zignego AL, Izzo F, Tornesello ML, Buonaguro FM, Mangia A, et al. Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. *PLoS One*. 2015 Feb 20;10(2): e 0117420. I F 4.41.
96. Terczyńska-Dyla E, Bibert S, Duong FH, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Malinverni R, Mangia A et al Reduced IFN λ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat. Commun*. 2014 Dec 23; 5:5699. IF 10.742.
97. Mangia A, Piazzolla V. Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. *Dig Liver Dis*. 2014 Dec 15; 46S5:S179-S185. doi: 10.1016/j.dld.2014.09.026. IF 2.89.
98. Mangia A, et al Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. *PLoS One*. 2014;9 (10): e110284. IF 3.53.
99. Bruno S, Bollani S, Zignego AL, Pascasio JM, Magni C, Ciancio A, Caremani M, Mangia A, et al; Italian and Spanish (IAS)-BoC Study Group. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International

Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. *J Viral Hepat.* 2014 Oct 14. doi: 10.1111/jvh.12342. [Epub ahead of print] IF 3.31.

100. Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M et al Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. *PlosOne* 2014; DOI 10.1371/journal.pone.0110284 IF3.23.
101. Morard I, Clément S, Calmy A, Mangia A, and Swiss Hepatitis C Cohort Study Group Clinical Significance of the CCR5delta32 Allele in Hepatitis C. *PLoS One.* 2014 Sep 5;9(9):106424 IF 3.53.
102. Capone F, Guerriero E, Colonna G, Maio P, Mangia A, et al Cytokine profile evaluation in patients with hepatitis C virus infection. *World J Gastroenterol.* 2014 Jul 28;20(28):9261-9. IF 2.5.
103. Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A. Interleukin-28B genetic variants in untreated Italian HCV-infected patients: multicentre study. *Liver Int.* 2015, 35:482-8 IF 3.84.
104. Zignego AL, Wojcik GL, Cacoub P, Visentini M, Casato M, Mangia A, et al Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. *Genes Immun.* 2014;15 (7):500-5. IF 3.79.
105. Angelico R, Ceglie A, Sacco P, Colafemmina G, Ripoli M, Mangia A. Phytoliposomes as nanoshuttles for water-insoluble silybin-phospholipid complex. *Int J Pharm.* 2014 Aug 25;471(1-2):173-81. IF 2.96.
106. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, et al Sofosbuvir and ribavirin in HCV genotypes 2 and 3. *N Engl J Med.* 2014 May 22;370(21):1993-2001. IF 55.87 .
107. Eslam M, Leung R, Romero-Gomez M, Mangia A, et al IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. *J Hepatol.* 2014 Aug;61(2):235-41 IF 9.56.
108. Afdhal N, Zeuzem S, Kwo P, Chojkier M; Gitlin N et al Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med.* 2014 May 15;370(20):1889-98. IF 55.87.
109. De Re V, Gragnani L, Fognani E, Piluso A, Izzo F, Mangia A, et al Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. *Biomed Res Int.* 2014; 2014:710642. IF 2.1.
110. Mangia A, Ripoli M. Insulin resistance, steatosis and hepatitis C virus. *Hepatol Int.* 2013 Aug 27;7(Suppl 2):782-789. eCollection 2013 Dec IF 2.47.
111. Zavaglia C, Silini E, Mangia A, et al Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. *Liver Int.* 2014 Aug;34(7):308-16. IF 3.84

112. Mangia A, Mottola L, Santoro R. et al Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 infected patients. *World J Gastroenterol*. 2013 Dec 21;19 (47):8924-8 IF 2.55.
113. Mangia A, Bányaï T, De Bartolomeo G, Gervain J, Habersetzer F et al In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions. *Liver Int*. 2014 Aug;34 (7):217-28. IF 3.84.
114. Copetti M, Pellegrini F, Piazzolla V, Mangia A. Reply to: "Built-in bias in HCV clearance in acute HCV infection" *J Hepatol*. 2014 Feb; 60 (2):461-3 IF 9.56 .
115. Italian Association for the Study of the Liver (AISF), Coco B, Caraceni P, Aghemo A, Bitetto D, et al Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). *Dig Liver Dis*. 2014 Jan;46(1):18-24. IF 2.8.
116. Mangia A Hepatitis C and direct antivirals Hot Topics in viral Hepatitis 2013; 27:7-11
117. Lawitz E, Mangia A, Wyles D, Rodriguez-Torrez M, Hassanein T, Gordon SC et al Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med*. 2013 May 16; 68(20):1878-87 IF 54.42 .
118. Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, Cappucci G, Missale G, Mottola L, et al Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. *J Hepatol*. 2013 Aug; 59 (2):221-8 IF 9.56.
119. Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, Piazzolla V, Badea R, Laffi G, Marra F, Mangia A, Pinzani M. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. *Hepatology*. 2013 Jul;58(1):65-72. IF11.19.
120. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich et al Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. *Ann Intern Med*. 2013 Feb 19;158(4):235-45. IF 16.104 .
121. Bruno S, Mangia A Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis. *J Hepatol*. 2013 Jun;58(6):1259. IF 10.40.
122. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, et al SPRINT-2 Trial Investigators. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. *Hepatology*. 2013 Mar;57(3):974-84. IF11.19
123. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, et al ; SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. *Gastroenterology*. 2012 Sep;143(3):608-18.e1-5. IF 12.82.
124. Mangia A, Mottola L, Piazzolla V Update on treatment of patients with nongenotype 1 HCV infection *Clin Infect Dis*. 2013 May;56(9):1294-300. IF 9.1.
125. Bruno S, Mangia A Futility of antiviral treatments for hepatitis C: an evolving concept entering the direct antiviral agents' era *Dig Liver Dis*. 2013 May; 45(5):356-61. IF 2.805.
126. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci p, Horban A, Jensen D, Lenygel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torrez M et al High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHECY cohort confirm results from randomized clinical trials. *Hepatology* 2012; 56:2039-2050 IF 12.03.

127. Ciancio A, Andreone P, Kaiser S, Mangia A, Milella M, et al Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive IFN/ribavirin: an adjuvant role? *J Viral Hepat.* 2012 Jan;19 Suppl 1:52-9. IF 3.34.
128. Mangia A, Mottola L What's new in Genotype 2 Liver Int. 2012 Feb;32 Suppl 1:135-40. IF 3.4.
129. Mangia A, Santoro R, Sarli R, Mottola L, Piazzolla V, Petruzzellis D, Bacca D, Clemente R, Copetti M, di Mauro L, Lotti G, Sacco M, Stefano I. IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients. *Antivir Ther.* 2011;16(8):1309-16. IF 3.74.
130. Mangia A, Mottola L. Treatment of Non-Genotype 1 Hepatitis C Virus Patients. *Curr Gastroenterol Rep.* 2012 Feb;14(1):87-93 IF 0.1.
131. Barbano R, Copetti M, Perrone G, Pazienza V, Muscarella LA, Balsamo T, Storlazzi CT, Ripoli M, Rinaldi M, Valori VM, Latiano TP, Maiello E, Stanziale P, Carella M, Mangia et al High AD51 mRNA expression characterize estrogen receptor positive/progesterone receptor negative breast cancer and is associated with patient's outcome. *Int J Cancer.* 2011 Aug 1;129(3):536-45. IF 4.926.
132. Mangia A, Mottola L, Andriulli A. Altered Dosage or Duration of current antiviral therapy for HCV genotypes 2 and 3. *Advanced Therapy for hepatitis C*; 2011:97-10.
133. Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. *Aliment Pharmacol Ther.* 2011 Oct 28. [Epub ahead of print] IF 3.86.
134. Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non invasive fibrosis biomarkers: an international study of 2411 cases. *Aliment Pharmacol Ther.* 2011 Nov;34(10):1202-1216. Epub 2011 Oct 9. IF 3.6.
135. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, Di Nubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med.* 2011 Mar 31;364(13):1195-206. IF 53.49.
136. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV/3 but do not decrease dose reductions of RBV or increase SVR. *Hepatology.* 2011 Feb;53(2):389-95. IF 10.89.
137. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB; Pharmacogenetics and Hepatitis C Meeting Participants. Hepatitis C pharmacogenetics: state of the art in 2010. *Hepatology.* 2011 Jan;53(1):336-45. IF 10.89.
138. Mangia A. IL28B: A new wager in the skyline of hepatitis C virus infection. *Dig Liver Dis.* 2011 Mar;43(3):177-9. IF 2.805
139. Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A, Buti M, Sheppard F, Ferenci P, Thévenot T. Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized controlled trials and implications for the future. *Hepatology.* 2011 Sep 2;54(3):789-800. IF 10.89.
140. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, Minerva N, Petruzzellis D, Mottola L, Bacca D, McHutchison JG. Limited utility of IL28B in the setting of

- response-guided treatment with detailed on-treatment virological monitoring. *Hepatology*. 2011 Sep 2;54(3):772-80. IF 10.89.
141. Guido M, Mangia A, Faa G; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Chronic viral hepatitis: the histology report. *Dig Liver Dis*. 2011 Mar;43 Suppl 4: S331-43. IF 2.805
 142. Mangia A. Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients *Liver Int*. 2011 Jan;31(1):36-41. IF 3.840.
 143. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB,McHutchison JG, Mangia A. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. *Hepatology*. 2011 Feb;53(2):389-95. IF 10.89.
 144. Mangia A, Bandiera F, Montalto G, Mottola L, Piazzolla V, Minerva N, Pellicelli A, Ricci GL, Cela M, Carretta V, Scotto G, Bacca D, Annicchiarico B, Romano M, Russello M, Barbarini G, Agostinacchio E, Andriulli A. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. *J Hepatol*. 2010 Dec;53(6):1000-5. IF 9.34.
 145. Mangia A, Andriulli A. Optimal dosage of ribavirin. *Hepatology*. 2010 Sep;52(3):1174. IF 10.89.
 146. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. *Gastroenterology*. 2010 Sep;139(3):821-7, IF 12.032.
 147. Paziienza V, Vinciguerra M, Andriulli A, Mangia A. HCV core protein genotype 3a increases SOCS-7 expression through PPAR- {gamma} in Huh-cells. *J Gen Virol*. 2010 Jul;91(Pt 7):1678-86. IF 3.568.
 148. Mangia A, Andriulli A. Tailoring the length of antiviral treatment for hepatitis C. *Gut*. 2010 Jan;59(1):1-5. IF 10.614
 149. Mangia A, Piazzolla V, Andriulli A. Management of patients with genotype 3 chronic hepatitis C: can we change the duration of therapy? *Clinical dilemmas in viral liver diseases*; 2010, 88-93.
 150. Mangia A, Dalgard O, Minerva N, Verbaan H et al Ribavirin dosage in HCV genotypes 2 and 3 patients completing short therapy with peg interferon alfa-2b and ribavirin. *Aliment Pharmacol Ther*. 2010 Mar 8. IF 3.86.
 151. Prati D, Gasbarrini A, Mazzotta F, et al for the Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. *Dig Liver Dis*. 2010 Feb;42(2):81-91. IF 2.805.
 152. Dalgard O, Mangia A. Management of patients with hepatitis C virus genotype 2 or 3: comments on updated American Association for the Study of Liver Diseases practice guidelines. *Hepatology*. 2009 Jul; 50(1):323 (author reply). IF 10.89.
 153. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. *Hepatology*. 2009 Jun;49(6):1821-7. PubMed PMID: 19291784. IF 10.89
 154. Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G,Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, Andriulli A.

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection *Hepatology*. 2009 Feb;49(2):358-63. PubMed PMID: 19072829. IF 10.89.

155. Paziienza V, Clément S, Pugnale P, Conzelmann S, Pascarella S, Mangia A, Negro F. Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins. *Liver Int*. 2009 May;29(5):661-9. IF 3.40.
156. Andriulli A, Cursaro C, Cozzolongo R, Iacobellis A, Valvano MR, Mangia A, Minerva N, Bacca D, Stanzione M, Scuteri A, Montalto G, Andreone P. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin. *J Viral Hepat*. 2009 Jan;16(1):28-35. IF 3.38.
157. Mangia A, Andriulli A. Are HCV genotype 2 and 3 the same or different? Current hepatitis reports, 2008; 7:88-92. Dalgard O, Mangia A. Short treatment to patients with genotype 2 or 3. *Hepatology*. 2008 Aug;48(2):694. IF 10.89. 112) Mangia A, Andriulli A. Reply. *Hepatology* 2008; 48:1020-1021. IF 10.89.
158. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, Di Costanzo G, Pastore G, Aghemo A, Stornaiuolo G, Mangia A, Andreone P, Stanzione M, Mazzella G, Saracco G, Del Poggio P, Bruno S; Italian Association of the Study of the Liver Disease (AISF). Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. *Am J Gastroenterol*. 2008 Aug;103(8):1966-72. IF 6.882.
159. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. *Aliment Pharmacol Ther*. 2008 Aug 15;28(4):397-404. IF 3.86.
160. Mangia A, Antonucci F, Brunetto M, Capobianchi M, Faggioli S, Guido M, Farci P, Lampertico P, Marzano A, Niro G, Pisani G, Prati D, Puoti M, Raimondo G, Santantonio T, Smedile A, Lauria F; Italian Association for the Study of the Liver (AISF). The use of molecular assays in the management of viral hepatitis. *Dig Liver Dis*. 2008 Jun;40(6):395-404. Epub 2008 Mar 5. IF 2.805.
161. Mangia A, Burra P, Ciancio A, Faggioli S, Guido M, Picciotto A, Fabrizi F; Italian Association for The Study of the Liver (A.I.S.F). Hepatitis C infection in patients with chronic kidney disease. *Int J Artif Organs*. 2008 Jan;31(1):15-33. (Review). IF 1.417.
162. De Compadri P, Koleva D, Mangia A, Motterlini N, Stat Sci N, Garattini L. Cost minimisation analysis of 12 or 24 weeks of peg-interferon alfa-2b + ribavirin for hepatitis C virus. *J Med Econ*. 2008;11(1):151-63. IF 0.1.
163. Mangia A, Andriulli A Reply to DR Yu and colleagues *Hepatology* 2008; 48:3
164. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. *Hepatology*. 2008 Jan;47(1):43-50. IF 10.89.
165. Andriulli A, Mangia A. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV. *N Engl J Med*. 2007 Oct 18;357(16):1660; author reply 1661-2. IF 53.49.
166. Guliani M, Lajolo C, Miani MC, Lodi G, Minenna P, Mangia A. Hepatitis C virus infection and oral lichen planus: an Italian case-control study. *Eur J of Gastroenterol and Hepatol* 2007; 19:647-652.
167. Paziienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. *Hepatology*. 2007 May;45(5):1164-71. IF 10.89.
168. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Faggioli S, Grossi P, Lampertico P, Meliconi R,

- Mangia A, et Prophylaxis and treatment of hepatitis B in immunocompromised patients. *Dig Liver Dis.* 2007 May; 39(5):397-408. IF 2.85.
169. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, et al Sustained virological response to interferon-alpha is associated with improved outcome in HCV related cirrhosis: a retrospective study. *Hepatology.* 2007 Mar;45(3):579-87. IF 10.89.
 170. Mangia A. Short-duration therapy for hepatitis C: suitable for all? *J Viral Hepat.* 2007 Apr;14(4):221-7. IF 3.38.
 171. Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. *Drugs.* 2006;66(14):1807-15. Review. IF 3.78.
 172. Andriulli A, Dalgard O, Bjørø K, Mangia A. Short-term treatment duration for HCV-2 and HCV-3 infected patients. *Dig Liver Dis.* 2006 Oct;38(10):741-8. IF 2.85.
 173. Latiano A, De Giorgio R, Volta U, Palmieri O, Zagaria C, Stanghellini V, Barbara G, Mangia A, Andriulli A, Corinaldesi R, Annese V. HLA and enteric antineuronal antibodies in patients with achalasia. *Neurogastroenterol Motil.* 2006 Jul;18(7):520-5. IF 3.68.
 174. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T et al HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology.* 2006 May;130(6):1636-42. IF 12.2.
 175. Iacobellis A, Fusilli S, Mangia A, Clemente R et al Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. *Aliment Pharmacol Ther.* 2005 Nov 1;22(9):769-74. IF 3.86.
 176. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 *N Engl J Med.* 2005 Jun 23; 352(25):2609-17. IF 53.49.
 177. Borg BB, Hoofnagle JH, Henry MJ, Mangia A, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection. *N Engl J Med* 2005; 353:1182-1183. IF 53.49.
 178. Mangia A, Villani MR, Cappucci G, Santoro R, Ricciardi R et al Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. *Eur J Gastroenterol Hepatol.* 2005 Jul; 17(7):745-51. IF 1.66.
 179. Giacobbe A, Iacobellis A, Facciorusso D, Federici T, Piermanni V, Mangia A, Niro G, Armillotta M. Unusual sonographic appearance of haemorrhagic biliary cyst. *European Journal of Radiology* 2005; 54:103-105 IF 2.3.
 180. Mangia A, Ricci GL, Persico M, Minerva N et al A. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. *J Viral Hepat.* 2005 May;12(3):292-9. IF 3.48
 181. Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne B, Pugnale P, Rossi C, Mangia A, Negro F. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. *J Hepatol.* 2005 May;42(5):744-51. PubMed PMID: 15826725. IF 9.334
 182. Iacobellis A, Mangia A, Leandro G, Clemente R, Festa V, Attino V, Ricciardi R, Giacobbe A, Facciorusso D, Andriulli A. External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. *Am J Gastroenterol.* 2005 Apr;100(4):868-73. PubMed PMID: 15784034. IF 6.882.

183. Andriulli A, Persico M, Iacobellis A, Maio G, Di Salvo D, Spadaccini A, Bacca D, Leandro G, Ventrella F, Mangia A. Treatment of patients with HCV infection with or without liver biopsy. *J Viral Hepat.* 2004 Nov;11(6):536-42. IF 3.348.
184. Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, Foster GR, Zeuzem S, Berg T, Di Marco V, Cino N, Andriulli A. Combination therapy with amantadine and interferon in naïve patients with chronic hepC: meta analysis of individual patient data from six clinical trials. *J Hepatol.* 2004 Mar;40(3):478-83. IF 9.334.
185. Mangia A, Spinzi G, Vuturo O, Pazienza V, Iacobelli A, Piattelli M et al Viral clearance in HCV viremic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. *Aliment Pharmacol Ther.* 2004 Feb 1;19(3):331-7. IF 3.6.
186. Mangia A, Santoro R, Piattelli M, Pazienza V, Grifa G, Iacobellis A, Andriulli A. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. *Cytokine.* 2004 Feb 7;25(3):103-9. IF 3.123.
187. Puoti C, Guido M, Mangia A, Persico M, Prati D; Committee on HCV carriers with normal alanine aminotransferase levels of the Italian Association for the Study of the Liver. Clinical management of HCV carriers with normal aminotransferase levels. *Dig Liver Dis.* 2003 May;35(5):362-9. IF 2.805.
188. Mangia A, Santoro R, D'Agruma L, Andriulli A. HCV chronic infection and CCR5 delta32/delta32. *Gastroenterology.* 2003 Mar;124(3):868-9 IF 12.032.
189. Cammà C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AG, Mangia A, Andriulli A, Puoti M, Spadaro A, Freni M, Di Marco V, Cino L, Saracco G, Chiesa A, Crosignani A, Caporaso N, Morisco F, Rumi MG, Craxì A. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. *Gut.* 2002 Dec;51(6):864-9. IF 10.614
190. Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E. Monitoring drug resistance in chronic hepatitis B virus (HBV) -infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. *J Clin Microbiol.* 2002 Oct;40(10):3729-34. IF 4.20.
191. Mangia A, Santoro R, Piattelli M, Leandro G, Minerva N, Annese M, Bacca D, Spirito F, Carretta V, Ventrella F, Cela M, Andriulli A. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. *J Hepatol.* 2002 Jul;37(1):109-16. IF 9.34.
192. Rosina F, Conoscitore P, Smedile A, Mangia A, Borghesio E, Martinotti R, Andriulli A, Rizzetto M. Treatment of chronic hepatitis D with thymus-derived polypeptide thyme humoral factor gamma 2: A pilot study. *Dig Liver Dis.* 2002 Apr;34(4):285-9. IF 2.8.
193. Andriulli A, Mangia A, Niro G, Caturelli E. To biopsy or not to biopsy. *Hepatology.* 2001 Aug; 34(2):438-9. IF 10.89.
194. Mangia A, Villani MR, Minerva N, Leandro G, Bacca D, Cela M, Carretta V, Attino V, Ventrella F, Giangaspero A, Andriulli A. Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial *J Hepatol* 2001; 34:441-446.
195. Mangia A, Leandro G, Villani MR, Santoro R, Minerva N, Annese M, Carretta V, Bacca D, Giangaspero A, Bisceglia M, Ventrella F, Dell'Erba G, Andriulli A. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. *Hepatology.* 2001 Apr; 33(4):989-993. IF 10.89
196. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, Villani MR, Facciorusso D, Conoscitore P, Spirito F, De Maio G. Pharmacologic treatment

- can prevent pancreatic injury after ERCP: a meta-analysis. *Gastrointest Endosc.* 2000 Jan;51(1):1-7. IF 5.64.
197. Mangia A, Margaglione M, Cascavilla I, Gentile R, Cappucci G, Facciorusso D, Grandone E, Di Minno G, Rizzetto M, Andriulli A. Anticardiolipin antibodies in patients with liver disease. *Am J Gastroenterol.* 1999 Oct;94(10):2983-7. IF 6.882.
 198. Mangia A, Andriulli A, Zenarola P, Lomuto M, Cascavilla I, Quadri R, Negro F. Lack of hepatitis C virus replication intermediate RNA in diseased skin tissue of chronic hepatitis C patients *J Med Virol.* 1999 Nov;59(3):277-80. IF 2.895.
 199. Mangia A, Gentile R, Cascavilla I, Margaglione M, Villani MR, Stella F, Modola G, Agostiano V, Gaudiano C, Andriulli A. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. *J Hepatol.* 1999 Jun;30(6):984-9. IF 9.3.
 200. Papa S, Rinaldi M, Mangia A, Parrella P, Signori E, Lombardi L, Fazio VM. Development of a multigenic plasmid vector for HCV DNA immunization. *Res Virol.* 1998 Sep-Oct;149(5):315-9. IF 0.1.
 201. Mangia A, Schiavone G, Lezzi G, Marmo R, Bruno F, Villani MR, Cascavilla I, Fantasia L, Andriulli A. HCV and diabetes mellitus: evidence for a negative association. *Am J Gastroenterol.* 1998 Dec;93(12):2363-7. PubMed PMID: 9860393. IF 6.88.
 202. International Interferon- α Hepatocellular Carcinoma Study Group. Effect of interferon- α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. *Lancet.* 1998; 351:1535-9. IF 33.63.
 203. Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F, Gallo V, Chaindussi L, Donada C, Donadon V, Spirito F, Mangia A, Andriulli A, Verme G et al. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alfa-2b for chronic hepatitis type C. Results of a multicentre randomized trial *J Hepatol* 1997; 27:56-62.
 204. Mangia A, Cascavilla I, Lezzi G, Spirito F, Maertens G, Parlatore L, Saracco G, Rizzetto M, Andriulli A. HCV genotypes in patients with liver disease of different stages and severity. *J Hepatol.* 1997 Jun;26(6):1173-8. IF 9.34.
 205. Sagnelli E, Gaeta GB, Felaco FM, Stroffolini, Conti S et al Hepatitis C infection in Households of antiHCV chronic carriers in Italy: a multicentre case-control study. *Infection* 1997;25:346-349
 206. Mangia A, Chung YH, Hoofnagle JH, Birkenmeyer L, Mushahwar I, Di Bisceglie AM. Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. *Dig Dis Sci.* 1996 Dec;41(12):2447-52. IF 2.60.
 207. Musto P, Dell'Olio M, Carotenuto M, Mangia A, Andriulli A. Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists *Blood.* 1996 Jul 15;88(2):752-4. PubMed PMID: 8695825. IF 10.58.
 208. Mangia A, Clemente R, Musto P, Cascavilla I, La Floresta P, Sanpaolo G, Gentile R, Viglotti ML, Facciorusso D, Carotenuto M, Rizzetto M, Andriulli A Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. *Leukemia.* 1996 Jul;10(7):1209-13. PubMed PMID: 8684003. IF 8.96.
 209. Mangia A. Towards new quantitative tests. *Minerva Gastroenterol Dietol.* 1995 Mar;41(1):11-5. IF 0.12.
 210. Mangia A, Vallari DS, Di Bisceglie AM. Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma. *J Med Virol.* 1994 Jun;43(2):125-8. PubMed PMID: 7521900. IF 2.895.
 211. Smedile A, Mangia A, Brunetto MR, Giarin M, Marzano A, Ottobrelli A, Chiaberge E, Durazzo M, Bonino F, Verme G, et al. Different aspects of HDV and HBV reinfections and liver disease in orthotopic liver transplant (OLT). *Prog Clin Biol Res.* 1993; 382:393-402. PubMed PMID: 8502709. IF 0.1.

212. Brunetto MR, Giarin MM, Rosina F, Smedile A, Mangia A, et al Relations between hepatitis delta virus pathogenicity and hepatitis B virus heterogeneity. *Prog Clin Biol Res.* 1993; 382:213-9. PubMed PMID: 8502684. IF 0.1.
213. Caturelli E, Squillante MM, Fusilli S, Aliotta A, Cellerino C, Mangia A, Gabbrielli L. Gallbladder emptying in patients with primary achalasia. *Digestion.* 1992;52(3-4):152-6. IF 2.146.
214. Andriulli A, Mangia A, Lawson F. [Antisecretory drugs, hypergastrinemia and hyperplasia of enterochromaffin-like cells (ECL)]. *Minerva Dietologica e Gastroenterologica* 1991;Jul-Sep;37(3):135-40. (Review). IF 0.1.
215. Caturelli E, Sperandeo G, Squillante MM, Mangia A, Gabbrielli L. Cruveilhier-Baumgarten syndrome without esophageal varices: ultrasonographic diagnosis and echo-doppler study. *J Clin Gastroenterol.* 1989 Jun;11(3):357-61. PubMed PMID: 2666500. IF 2.752.
216. Altomonte L, Zoli A, Mirone L, Mangia A, Masucci M, Ghirlanda G, Greco AV. Serum C4 concentration and diabetic microangiopathy in insulin dependent diabetes. A study of an Italian group of insulin dependent diabetic patients. *Panminerva Med.* 1987 Oct-Dec;29(4):307-10. IF 0.1.
217. Altomonte L, Zoli A, Mangia A, Ghirlanda G, Manna R, Bertoli A, Greco AV. Thromboxane production in diabetes mellitus. *Ric Clin Lab.* 1986 Oct-Dec;16(4):539-42. PubMed PMID: 3576051. IF 0.1
218. Altomonte L, Zoli A, Accili D, Mangia A, Bianco A, Magarò M. Thrombosis, recurrent abortions and intrauterine fetal death in a patient with lupus anticoagulant. *Clin Rheumatol.* 1985 Dec;4(4):455-7. PubMed PMID: 3938355. IF 1.687.
219. Pepe M, Altomonte L, Palumbo P, Zoli A, Mangia A. Arterial hypertension with hypopotassemia and hypochloremic metabolic alkalosis caused by abuse of a nasal spray. *Minerva Med.* 1983 Oct 13;74(39):2323-6. Italian. PubMed PMID: 6197683. IF 0.49

San Giovanni Rotondo, 29 Dicembre, 2022

Alessandra Mangia, MD